STAT3 and neoplasm: In this model, the SMAD2/3 and STAT3 signaling pathways are activated in tumor cells as shown using CHLA-255 SMAD2/3 and STAT3 Fluc reporter cell lines, and activation is inhibited by lenalidomide (Supplementary Figure 6A and 6B).